|
1
|
Rees JD, Wilson AM and Wolman RL: Current
concepts in the management of tendon disorders. Rheumatology
(Oxford). 45:508–521. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Järvinen TA, Kannus P, Maffulli N and Khan
KM: Achilles tendon disorders: etiology and epidemiology. Foot
Ankle Clin. 10:255–266. 2005.
|
|
3
|
Wang JH, Iosifidis MI and Fu FH:
Biomechanical basis for tendinopathy. Clin Orthop Relat Res.
443:320–332. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hoffmann A and Gross G: Tendon and
ligament engineering: from cell biology to in vivo application.
Regen Med. 1:563–574. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kuo CK, Marturano JE and Tuan RS: Novel
strategies in tendon and ligament tissue engineering: Advanced
biomaterials and regeneration motifs. Sports Med Arthrosc Rehabil
Ther Technol. 2:202010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bruder SP, Fink DJ and Caplan AI:
Mesenchymal stem cells in bone development, bone repair, and
skeletal regeneration therapy. J Cell Biochem. 56:283–294. 1994.
View Article : Google Scholar
|
|
7
|
Jorgensen C, Gordeladze J and Noel D:
Tissue engineering through autologous mesenchymal stem cells. Curr
Opin Biotechnol. 15:406–410. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Studeny M, Marini FC, Champlin RE,
Zompetta C, Fidler IJ and Andreeff M: Bone marrow-derived
mesenchymal stem cells as vehicles for interferon-beta delivery
into tumors. Cancer Res. 62:3603–3608. 2002.PubMed/NCBI
|
|
9
|
Khakoo AY, Pati S, Anderson SA, et al:
Human mesenchymal stem cells exert potent antitumorigenic effects
in a model of Kaposi’s sarcoma. J Exp Med. 203:1235–1247.
2006.PubMed/NCBI
|
|
10
|
Wu X, Chen S, Orlando SA, et al: p85alpha
regulates osteoblast differentiation by cross-talking with the MAPK
pathway. J Biol Chem. 286:13512–13521. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Giuliani N, Bataille R, Mancini C,
Lazzaretti M and Barillé S: Myeloma cells induce imbalance in the
osteoprotegerin/osteoprotegerin ligand system in the human bone
marrow environment. Blood. 98:3527–3533. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Powers CJ, McLeskey SW and Wellstein A:
Fibroblast growth factors, their receptors and signaling. Endocr
Relat Cancer. 7:165–197. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yu PJ, Ferrari G, Galloway AC, Mignatti P
and Pintucci G: Basic fibroblast growth factor (FGF-2): the high
molecular weight forms come of age. J Cell Biochem. 100:1100–1108.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
van den Bos C, Mosca JD, Winkles J,
Kerrigan L, Burgess WH and Marshak DR: Human mesenchymal stem cells
respond to fibroblast growth factors. Hum Cell. 10:45–50.
1997.PubMed/NCBI
|
|
15
|
Tsutsumi S, Shimazu A, Miyazaki K, et al:
Retention of multilineage differentiation potential of mesenchymal
cells during proliferation in response to FGF. Biochem Biophys Res
Commun. 288:413–419. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bianchi G, Banfi A, Mastrogiacomo M, et
al: Ex vivo enrichment of mesenchymal cell progenitors by
fibroblast growth factor 2. Exp Cell Res. 287:98–105. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Baddoo M, Hill K, Wilkinson R, et al:
Characterization of mesenchymal stem cells isolated from murine
bone marrow by negative selection. J Cell Biochem. 89:1235–1249.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Choi SC, Kim SJ, Choi JH, Park CY, Shim WJ
and Lim DS: Fibroblast growth factor-2 and -4 promote the
proliferation of bone marrow mesenchymal stem cells by the
activation of the PI3K-Akt and ERK1/2 signaling pathways. Stem
Cells Dev. 17:725–736. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Masola V, Gambaro G, Tibaldi E, et al:
Heparanase and syndecan-1 interplay orchestrates fibroblast growth
factor-2-induced epithelial-mesenchymal transition in renal tubular
cells. J Biol Chem. 287:1478–1488. 2012. View Article : Google Scholar
|
|
20
|
Solchaga LA, Penick K, Porter JD, Goldberg
VM, Caplan AI and Welter JF: FGF-2 enhances the mitotic and
chondrogenic potentials of human adult bone marrow-derived
mesenchymal stem cells. J Cell Physiol. 203:398–409. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Varas L, Ohlsson LB, Honeth G, et al:
Alpha10 integrin expression is up-regulated on fibroblast growth
factor-2-treated mesenchymal stem cells with improved chondrogenic
differentiation potential. Stem Cells Dev. 16:965–978. 2007.
View Article : Google Scholar
|
|
22
|
Neubauer M, Fischbach C, Bauer-Kreisel P,
et al: Basic fibroblast growth factor enhances PPARgamma
ligand-induced adipogenesis of mesenchymal stem cells. FEBS Lett.
577:277–283. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lai WT, Krishnappa V and Phinney DG:
Fibroblast growth factor 2 (Fgf2) inhibits differentiation of
mesenchymal stem cells by inducing Twist2 and Spry4, blocking
extracellular regulated kinase activation, and altering Fgf
receptor expression levels. Stem Cells. 29:1102–1111. 2011.
View Article : Google Scholar
|
|
24
|
Frederick JP, Liberati NT, Waddell DS, Shi
Y and Wang XF: Transforming growth factor beta-mediated
transcriptional repression of c-myc is dependent on direct binding
of Smad3 to a novel repressive Smad binding element. Mol Cell Biol.
24:2546–2559. 2004. View Article : Google Scholar
|
|
25
|
Wang L, Blouin V, Brument N, Bello-Roufai
M and Francois A: Production and purification of recombinant
adeno-associated vectors. Methods Mol Biol. 807:361–404. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lanner F and Rossant J: The role of
FGF/Erk signaling in pluripotent cells. Development. 137:3351–3360.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ozaki K, Miyazaki S, Tanimura S and Kohno
M: Efficient suppression of FGF-2-induced ERK activation by the
cooperative interaction among mammalian Sprouty isoforms. J Cell
Sci. 118:5861–5871. 2005. View Article : Google Scholar : PubMed/NCBI
|
